{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:02Z","timestamp":1777870382968,"version":"3.51.4"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T00:00:00Z","timestamp":1548115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002790","name":"Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"crossref","award":["RGPIN-2015-03733"],"award-info":[{"award-number":["RGPIN-2015-03733"]}],"id":[{"id":"10.13039\/501100002790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s40620-018-00578-8","type":"journal-article","created":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T19:37:04Z","timestamp":1548272224000},"page":"401-409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cyclooxygenase 2 inhibition slows disease progression and improves the altered renal lipid mediator profile in the Pkd2WS25\/\u2212 mouse model of autosomal dominant polycystic kidney disease"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-3530","authenticated-orcid":false,"given":"Md","family":"Monirujjaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6982-7239","authenticated-orcid":false,"given":"Harold M.","family":"Aukema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,1,22]]},"reference":[{"key":"578_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.med.60.101707.125712","volume":"60","author":"PC Harris","year":"2009","unstructured":"Harris PC, Torres VE (2009) Polycystic kidney disease. Annu Rev Med 60:321\u2013337","journal-title":"Annu Rev Med"},{"key":"578_CR2","first-page":"212275","volume":"4","author":"CM Blanchette","year":"2015","unstructured":"Blanchette CM, Liang C, Lubeck DP, Newsome B, Rossetti S, Gu X, Gutierrez B, Lin ND (2015) Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease. Drugs Context 4:212275","journal-title":"Drugs Context"},{"key":"578_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13393","author":"F Luo","year":"2018","unstructured":"Luo F, Tao YH (2018) Nephronophthisis: a review of genotype\u2013phenotype correlation. Nephrology (Carlton). \n                    https:\/\/doi.org\/10.1111\/nep.13393","journal-title":"Nephrology (Carlton)"},{"key":"578_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40620-017-0395-9","volume":"30","author":"R Magistroni","year":"2017","unstructured":"Magistroni R, Boletta (2017) Defective glycolysis and the use of 2-deoxy-d-glucose in polycystic kidney disease: from animal models to humans. J Nephrol 30:511\u2013519","journal-title":"J Nephrol"},{"key":"578_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0272-6386(12)80179-X","volume":"24","author":"JH Stewart","year":"1994","unstructured":"Stewart JH (1994) End-stage renal failure appears earlier in men than in women with polycystic kidney disease. Am J Kidney Dis 24:181\u2013183","journal-title":"Am J Kidney Dis"},{"key":"578_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.plefa.2014.11.009","volume":"94","author":"T Yamaguchi","year":"2015","unstructured":"Yamaguchi T, Devassy JG, Gabbs M, Ravandi A, Nagao S, Aukema HM (2015) Dietary flax oil rich in alpha-linolenic acid reduces renal disease and oxylipin abnormalities, including formation of docosahexaenoic acid derived oxylipins in the CD1-pcy\/pcy mouse model of nephronophthisis. Prostaglandins Leukot Essent Fatty Acids 94:83\u201389","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"578_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11745-013-3859-2","volume":"49","author":"T Yamaguchi","year":"2014","unstructured":"Yamaguchi T, Lysecki C, Reid A, Nagao S, Aukema HM (2014) Renal cyclooxygenase products are higher and lipoxygenase products are lower in early disease in the pcy mouse model of adolescent nephronophthisis. Lipids 49:39\u201347","journal-title":"Lipids"},{"key":"578_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/mnfr.201300332","volume":"58","author":"NH Ibrahim","year":"2014","unstructured":"Ibrahim NH, Jia Y, Devassy JG, Yamaguchi T, Aukema HM (2014) Renal cyclooxygenase and lipoxygenase products are altered in polycystic kidneys and by dietary soy protein and fish oil treatment in the Han:SPRD-Cy rat. Mol Nutr Food Res 58:768\u2013781","journal-title":"Mol Nutr Food Res"},{"key":"578_CR9","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.bbalip.2017.08.005","volume":"1862","author":"M Monirujjaman","year":"2017","unstructured":"Monirujjaman M, Devassy JG, Yamaguchi T, Sidhu N, Kugita M, Gabbs M, Nagao S, Zhou J, Ravandi A, Aukema HM (2017) Distinct oxylipin alterations in diverse models of cystic kidney diseases. Biochim Biophys Acta 1862:1562\u20131574","journal-title":"Biochim Biophys Acta"},{"key":"578_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3945\/an.114.007732","volume":"6","author":"M Gabbs","year":"2015","unstructured":"Gabbs M, Leng S, Devassy JG, Monirujjaman M, Aukema HM (2015) Advances in our understanding of oxylipins derived from dietary PUFAs. Adv Nutr 6:513\u2013540","journal-title":"Adv Nutr"},{"key":"578_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/MNH.0b013e32831a9df7","volume":"18","author":"NO Camara","year":"2009","unstructured":"Camara NO, Martins JO, Landgraf RG, Jancar S (2009) Emerging roles for eicosanoids in renal diseases. Curr Opin Nephrol Hypertens 18:21\u201327","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"578_CR12","doi-asserted-by":"publisher","first-page":"F897","DOI":"10.1152\/ajprenal.00332.2005","volume":"290","author":"L Warford-Woolgar","year":"2006","unstructured":"Warford-Woolgar L, Peng CY, Shuhyta J, Wakefield A, Sankaran D, Ogborn M, Aukema HM (2006) Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRD-cy rat kidneys. Am J Physiol Renal Physiol 290:F897\u2013F904","journal-title":"Am J Physiol Renal Physiol"},{"key":"578_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1096\/fj.02-0460fje","volume":"17","author":"HM Aukema","year":"2003","unstructured":"Aukema HM, Adolphe J, Mishra S, Jiang J, Cuozzo FP, Ogborn MR (2003) Alterations in renal cytosolic phospholipase A2 and cyclooxygenases in polycystic kidney disease. FASEB J 17:298\u2013300","journal-title":"FASEB J"},{"key":"578_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.biocel.2003.08.006","volume":"36","author":"CL Bos","year":"2004","unstructured":"Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH (2004) Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36:1187\u20131205","journal-title":"Int J Biochem Cell Biol"},{"key":"578_CR15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1042\/BJ20111052","volume":"443","author":"MD Diaz-Munoz","year":"2012","unstructured":"Diaz-Munoz MD, Osma-Garcia IC, Fresno M, I\u00f1iguez MA (2012) Involvement of PGE2 and the cAMP signalling pathway in the up-regulation of COX-2 and mPGES-1 expression in LPS-activated macrophages. Biochem J 443:451\u2013461","journal-title":"Biochem J"},{"key":"578_CR16","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.bbamcr.2007.09.001","volume":"1773","author":"T Klein","year":"2007","unstructured":"Klein T, Shephard P, Kleinert H, K\u00f6mhoff M (2007) Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochim Biophys Acta 1773:1605\u20131618","journal-title":"Biochim Biophys Acta"},{"key":"578_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0272-6386(97)90496-0","volume":"30","author":"T Yamaguchi","year":"1997","unstructured":"Yamaguchi T, Nagao S, Kasahara M, K\u00f6mhoff M (1997) Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30:703\u2013709","journal-title":"Am J Kidney Dis"},{"key":"578_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1681\/ASN.2006111218","volume":"18","author":"WC Putnam","year":"2007","unstructured":"Putnam WC, Swenson SM, Reif GA, Wallace DP, Helmkamp GM Jr, Grantham JJ (2007) Identification of a forskolin-like molecule in human renal cysts. J Am Soc Nephrol 18:934\u2013943","journal-title":"J Am Soc Nephrol"},{"key":"578_CR19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1046\/j.1523-1755.2000.00991.x","volume":"57","author":"T Yamaguchi","year":"2000","unstructured":"Yamaguchi T, Pelling JC, Ramaswamy NT, et Eppler JW, Wallace DP, Nagao S, Rome LA, Sullivan LP, Grantham JJ (2000) cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57:1460\u20131471","journal-title":"Kidney Int"},{"key":"578_CR20","doi-asserted-by":"publisher","first-page":"F1622","DOI":"10.1152\/ajprenal.00036.2007","volume":"293","author":"G Elberg","year":"2007","unstructured":"Elberg G, Elberg D, Lewis TV, Guruswamy S, Chen L, Logan CJ, Chan MD, Turman MA (2007) EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells. Am J Physiol Renal Physiol 293:F1622\u2013F1632","journal-title":"Am J Physiol Renal Physiol"},{"key":"578_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.prostaglandins.2012.03.005","volume":"98","author":"D Elberg","year":"2012","unstructured":"Elberg D, Turman MA, Pullen N, Elberg G (2012) Prostaglandin E2 stimulates cystogenesis through EP4 receptor in IMCD-3 cells. Prostaglandins Other Lipid Mediat 98:11\u201316","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"578_CR22","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1681\/ASN.2007070828","volume":"19","author":"B Yang","year":"2008","unstructured":"Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS (2008) Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 19:1300\u20131310","journal-title":"J Am Soc Nephrol"},{"key":"578_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ki.2008.246","volume":"74","author":"M Albaqumi","year":"2008","unstructured":"Albaqumi M, Srivastava S, Li Z, Zhdnova O, Wulff H, Itani O, Wallace DP, Skolnik EY (2008) KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int 74:740\u2013749","journal-title":"Kidney Int"},{"key":"578_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.prostaglandins.2014.10.005","volume":"116\u2013117","author":"NH Ibrahim","year":"2015","unstructured":"Ibrahim NH, Gregoire M, Devassy JG, Wu Y, Yoshihara D, Yamaguchi T, Nagao S, Aukema HM (2015) Cyclooxygenase product inhibition with acetylsalicylic acid slows disease progression in the Han:SPRD-Cy rat model of polycystic kidney disease. Prostaglandins Other Lipid Mediat 116\u2013117:19\u201325","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"578_CR25","doi-asserted-by":"publisher","first-page":"7743","DOI":"10.1007\/s11033-012-1611-2","volume":"39","author":"T Xu","year":"2012","unstructured":"Xu T, Wang NS, Fu LL, Ye CY, Yu SQ, Mei CL (2012) Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF\/Raf\/MAPK\/ERK signaling pathway. Mol Biol Rep 39:7743\u20137753","journal-title":"Mol Biol Rep"},{"key":"578_CR26","doi-asserted-by":"publisher","first-page":"F821","DOI":"10.1152\/ajprenal.00257.2006","volume":"293","author":"D Sankaran","year":"2007","unstructured":"Sankaran D, Bankovic-Calic N, Ogborn MR, Crow G, Aukema HM (2007) Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 293:F821\u2013F830","journal-title":"Am J Physiol Renal Physiol"},{"key":"578_CR27","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.3390\/ph3072291","volume":"3","author":"WH Horl","year":"2010","unstructured":"Horl WH (2010) Nonsteroidal anti-inflammatory drugs and the kidney. Pharmaceuticals (Basel) 3:2291\u20132321","journal-title":"Pharmaceuticals (Basel)"},{"key":"578_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0092-8674(00)81570-6","volume":"93","author":"G Wu","year":"1998","unstructured":"Wu G, D\u2019Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S (1998) Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93:177\u2013188","journal-title":"Cell"},{"key":"578_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11745-016-4228-8","volume":"52","author":"JM Olson","year":"2017","unstructured":"Olson JM, Haas AW, Lor J, McKee HS, Cook ME (2017) A Comparison of the anti-inflammatory effects of Cis-9, Trans-11 Conjugated linoleic acid to celecoxib in the collagen-induced arthritis model. Lipids 52:151\u2013159","journal-title":"Lipids"},{"key":"578_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1042\/CS20120543","volume":"124","author":"R Nasrallah","year":"2013","unstructured":"Nasrallah R, Robertson SJ, Karsh J, H\u00e9bert RL (2013) Celecoxib modifies glomerular basement membrane, mesangium and podocytes in OVE26 mice, but ibuprofen is more detrimental. Clin Sci (Lond) 124:685\u2013694","journal-title":"Clin Sci (Lond)"},{"key":"578_CR31","doi-asserted-by":"publisher","first-page":"e0155790","DOI":"10.1371\/journal.pone.0155790","volume":"11","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi T, Devassy JG, Monirujjaman M, Gabbs M, Aukema HM (2016) Lack of benefit of early intervention with dietary flax and fish oil and soy protein in orthologous rodent models of human hereditary polycystic kidney disease. PLoS One 11:e0155790","journal-title":"PLoS One"},{"key":"578_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11745-004-1221-7","volume":"39","author":"D Sankaran","year":"2004","unstructured":"Sankaran D, Lu J, Bankovic-Calic N, Ogborn MR, Aukema HM (2004) Modulation of renal injury in pcy mice by dietary fat containing n-3 fatty acids depends on the level and type of fat. Lipids 39:207\u2013214","journal-title":"Lipids"},{"key":"578_CR33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1044-0305(98)00013-0","volume":"9","author":"LM Hall","year":"1998","unstructured":"Hall LM, Murphy RC (1998) Electrospray mass spectrometric analysis of 5-hydroperoxy and 5-hydroxyeicosatetraenoic acids generated by lipid peroxidation of red blood cell ghost phospholipids. J Am Soc Mass Spectrom 9:527\u2013532","journal-title":"J Am Soc Mass Spectrom"},{"key":"578_CR34","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03650318","author":"AL Messchendorp","year":"2018","unstructured":"Messchendorp AL, van Londen M, Taylor JM, de Borst MH, Navis G, Casteleijn NF et al (2018) Kidney function reserve capacity in early and later stage autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. \n                    https:\/\/doi.org\/10.2215\/CJN.03650318","journal-title":"Clin J Am Soc Nephrol"},{"key":"578_CR35","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/cphy.c160018","volume":"7","author":"J Ghata","year":"2017","unstructured":"Ghata J, Cowley BD Jr (2017) Polycystic kidney disease. Compr Physiol 7:945\u2013975","journal-title":"Compr Physiol"},{"key":"578_CR36","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","volume":"63","author":"T Yamaguchi","year":"2003","unstructured":"Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ (2003) Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63:1983\u20131994","journal-title":"Kidney Int"},{"key":"578_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2017.08.005","volume":"93","author":"Q Wang","year":"2018","unstructured":"Wang Q, Cobo-Stark P, Patel V, Somlo S, Han PL, Igarashi P (2018) Adenylyl cyclase 5 deficiency reduces renal cyclic AMP and cyst growth in an orthologous mouse model of polycystic kidney disease. Kidney Int 93:403\u2013415","journal-title":"Kidney Int"},{"key":"578_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1681\/ASN.2013121312","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE (2015) Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol 26:39\u201347","journal-title":"J Am Soc Nephrol"},{"key":"578_CR39","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E et al (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367:2407\u20132418","journal-title":"N Engl J Med"},{"key":"578_CR40","doi-asserted-by":"publisher","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","volume":"301","author":"GA Reif","year":"2011","unstructured":"Reif GA, Yamaguchi T, Nivens E, Fujiki H, Pinto CS, Wallace DP (2011) Tolvaptan inhibits ERK-dependent cell proliferation, Cl(\u2212) secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol 301:F1005\u2013F1013","journal-title":"Am J Physiol Renal Physiol"},{"key":"578_CR41","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1210\/en.2003-0903","volume":"145","author":"MZ Zhang","year":"2004","unstructured":"Zhang MZ, Sanchez Lopez P, McKanna JA, Harris RC (2004) Regulation of cyclooxygenase expression by vasopressin in rat renal medulla. Endocrinology 145:1402\u20131409","journal-title":"Endocrinology"},{"key":"578_CR42","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1681\/ASN.2009121291","volume":"21","author":"MC Hogan","year":"2010","unstructured":"Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X et al (2010) Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21:1052\u20131061","journal-title":"J Am Soc Nephrol"},{"key":"578_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hep.26140","volume":"58","author":"TV Masyuk","year":"2013","unstructured":"Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF (2013) Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 58:409\u2013421","journal-title":"Hepatology"},{"key":"578_CR44","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1681\/ASN.2015060634","volume":"27","author":"R Lakhia","year":"2016","unstructured":"Lakhia R, Hajarnis S, Williams D, Aboudehen K, Yheskel M, Xing C, Hatley ME, Torres VE, Wallace DP, Patel V (2016) MicroRNA-21 aggravates cyst growth in a model of polycystic kidney disease. J Am Soc Nephrol 27:2319\u20132330","journal-title":"J Am Soc Nephrol"},{"key":"578_CR45","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","volume":"66","author":"FA1 Belibi","year":"2004","unstructured":"Belibi FA1, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H, Helmkamp GM Jr, Grantham JJ (2004) Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66:964\u2013973","journal-title":"Kidney Int"},{"key":"578_CR46","doi-asserted-by":"publisher","first-page":"e110267","DOI":"10.1371\/journal.pone.0110267","volume":"9","author":"O Peacock","year":"2014","unstructured":"Peacock O, Lee AC, Cameron F, Tarbox R, Vafadar-Isfahani N, Tufarelli C, Lund JN (2014) Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer. PLoS One 9:e110267","journal-title":"PLoS One"},{"key":"578_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14336\/AD.2017.0306","volume":"9","author":"S Wongrakpanich","year":"2018","unstructured":"Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J (2018) A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis 9:143\u2013150","journal-title":"Aging Dis"},{"key":"578_CR48","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1053\/sarh.2002.37217","volume":"32","author":"L Laine","year":"2002","unstructured":"Laine L (2002) The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 32:25\u201332","journal-title":"Semin Arthritis Rheum"},{"key":"578_CR49","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40620-016-0352-z","volume":"30","author":"Z Heleniak","year":"2017","unstructured":"Heleniak Z, Ciepli\u0144ska M, Szychli\u0144ski T, Rychter D, Jagodzi\u0144ska K, K\u0142os A, Ku\u017amiuk I, Tylicka MJ, Tylicki L, Rutkowski B, D\u0119bska-\u015alizie\u0144 A (2017) Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease. J Nephrol 30:781\u2013786","journal-title":"J Nephrol"},{"key":"578_CR50","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2165\/00002018-200225070-00007","volume":"25","author":"SR Ahmad","year":"2002","unstructured":"Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J (2002) Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 25:537\u2013544","journal-title":"Drug Saf"},{"key":"578_CR51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.arth.2015.08.012","volume":"31","author":"LC Warth","year":"2016","unstructured":"Warth LC, Noiseux NO, Hogue MH, Klaassen AL, Liu SS, Callaghan JJ (2016) Risk of acute kidney injury after primary and revision total hip arthroplasty and total knee arthroplasty using a multimodal approach to perioperative pain control including ketorolac and celecoxib. J Arthroplasty 31:253\u2013255","journal-title":"J Arthroplasty"},{"key":"578_CR52","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/jn\/134.6.1504","volume":"134","author":"DE Fair","year":"2004","unstructured":"Fair DE, Ogborn MR, Weiler HA, Bankovic-Calic N, Nitschmann EP, Fitzpatrick-Wong SC, Aukema HM (2004) Dietary soy protein attenuates renal disease progression after 1 and 3 weeks in Han:SPRD-cy weanling rats. J Nutr 134:1504\u20131507","journal-title":"J Nutr"},{"key":"578_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1017\/S0007114507250470","volume":"97","author":"LE Cahill","year":"2007","unstructured":"Cahill LE, Peng CY, Bankovic-Calic N, Sankaran D, Ogborn MR, Aukema HM (2007) Dietary soya protein during pregnancy and lactation in rats with hereditary kidney disease attenuates disease progression in offspring. Br J Nutr 97:77\u201384","journal-title":"Br J Nutr"},{"key":"578_CR54","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659\u2013661","journal-title":"FASEB J"},{"key":"578_CR55","doi-asserted-by":"publisher","first-page":"13266","DOI":"10.1073\/pnas.202296999","volume":"99","author":"L Jozsef","year":"2002","unstructured":"Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG (2002) Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA 99:13266\u201313271","journal-title":"Proc Natl Acad Sci USA"},{"key":"578_CR56","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1161\/01.HYP.0000176237.74820.75","volume":"46","author":"JD Imig","year":"2005","unstructured":"Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46:975\u2013981","journal-title":"Hypertension"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-018-00578-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-018-00578-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-018-00578-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:06Z","timestamp":1777564566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/32\/3\/401\/8328140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,22]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1007\/s40620-018-00578-8","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,22]]},"assertion":[{"value":"23 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of University of Manitoba.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}